Liquid Biopsy Propelling Cancer Diagnostics Research Is Focus of Mid-Morning Session on Day 2 of Personalized Medicine World Conference (PMWC) 2017 at Duke; GRAIL Founder Richard Klausner Speaks

Speakers in the mid-morning session of Day 2 of the PMWC 2017 at Duke focused on how “Liquid Biopsy Is Propelling Cancer Diagnostics Research.” The speakers included Richard Klausner, MD, former Director of the National Cancer Institute, past Chief Medical Officer at Illumina, and a founder of GRAIL, Inc. (https://grail.com/), a life sciences company whose mission is to detect cancer early, when it can be cured, using wide and deep DNA sequencing analysis of circulating cell-free DNA (cfDNA); John Beeler, PhD, VP of Corporate & Business Development, Inivata (https://www.inivata.com/), a company dedicated to transforming clinical cancer care with liquid biopsy; and Edward Kim, MD, Chair of Solid Tumor Oncology and Investigational Therapeutics and the Donald S. Kim Distinguished Chair for Cancer Research at the Levine Cancer Institute, Carolinas HealthCare System in Charlotte, North Carolina. Dr. Kim was previously at UT MD Anderson Cancer Center in Houston, Texas where he was a tenured Associate Professor of Medicine, Chief of the Section of Head and Neck Medical Oncology, and Director of Clinical Research Operations in the Department of Thoracic/Head and Neck Medical Oncology. Dr. Klausner began the session by briefly telling the story of how GRAIL, a company that recently raised $900 million in funding, came to be. The story began not too long ago at Illumina, the biotech company where Dr. Klausner was CMO.
Login Or Register To Read Full Story